Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | ATR | Q13535 | 5/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183931 | 0.90 | SIGMAR1 (0.37) | SIGMAR1ATRATRIPP2RY14DRD2 | |
| SCHEMBL4183936 | 0.90 | SIGMAR1 (0.37) | SIGMAR1ATRATRIPP2RY14DRD2 | |
| SCHEMBL5435573 | 0.88 | SIGMAR1 (0.40) | SIGMAR1P2RY14DRD2GSK3BALDH1A1 | |
| SCHEMBL3975810 | 0.88 | MTNR1A (0.41) | SIGMAR1P2RY14DRD2CYP2D6CYP2C19 | |
| SCHEMBL5433734 | 0.88 | SIGMAR1 (0.40) | SIGMAR1P2RY14DRD2GSK3BALDH1A1 | |
| SCHEMBL5433728 | 0.88 | SIGMAR1 (0.40) | SIGMAR1P2RY14DRD2GSK3BALDH1A1 | |
| SCHEMBL4183933 | 0.83 | SIGMAR1 (0.35) | SIGMAR1P2RY14DRD2CYP1A1CYP2D6 | |
| SCHEMBL4186478 | 0.82 | DDB1 (0.39) | SIGMAR1ATRATRIPALDH1A1 | |
| SCHEMBL4178090 | 0.82 | SIGMAR1 (0.37) | SIGMAR1AKT1P2RY14CYP2D6CYP2C19 | |
| SCHEMBL4134781 | 0.82 | DDB1 (0.40) | SIGMAR1P2RY14CNR2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080096829-A1 | Macrolone Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | SIGMAR1 1925/4885ATR 4662/4885ATRIP 4634/4885 |
| US-20080096829-A1 | Macrolone Compounds | MRPL21, MRPS18A, MRPL19 | SIGMAR1 601/4885ATR 4610/4885ATRIP 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.